Skip to content
Reduce pathological heart growth

A Spacer for Heart Health

Dortmund, 24th April 2020

The heart grows not only through sport, but also through illness. Researchers from Wuerzburg and Dortmund have now discovered a new possible point of attack for drugs to counteract this.

If the heart is heavily loaded, it reacts and grows. This happens, for example, during high sporting activity, especially endurance sports: the heart becomes stronger. In addition to this positive side of heart growth, however, there is also a dark side: If the heart is permanently stressed by a condition such as high blood pressure, the heart grows too much and heart failure can result.

An interdisciplinary team from the Julius Maximilian University (JMU) Wuerzburg and des Leibniz-Instituts für Analytische Wissenschaften (ISAS), led by ISAS Director Kristina Lorenz, has investigated the role of extracellularly regulated kinases (ERK) in pathological heart growth, identifying for the first time a protein sequence that can inhibit this damaging process. With the development of this sequence, the team has identified a potential target for drugs for use in cardiac insufficiency.

It usually takes several stress factors before the proverbial barrel overflows. This is similar in the smallest living units of the body, the cells. There, many protein molecules normally work together to ensure the survival of the cells. If too many stress factors come together, the protein molecules change their function and their cooperation in the cells is disturbed. The consequence: pathological cell growth, which can lead to heart failure. Because: If the enzymes ERK 1 and ERK 2 come close to each other, a biochemical change takes place, a so-called phosphorylation, which can trigger pathological heart growth.

Neonatale Kardiomyozyten gefärbt mit Phalloidin: Die Abbildung zeigt Herzmuskelzellen, blau ist der Zellkern und grün das Zytoskelett.

Neonatal cardiomyocytes stained with phalloidin: The figure shows heart muscle cells, blue is the nucleus and green the cytoskeleton. Picture: Constanze Schanbacher and Theresa Brand Neonatal cardiomyocytes stained with phalloidin: The figure shows heart muscle cells, blue is the nucleus and green the cytoskeleton.

© Constanze Schanbacher und Theresa Brand

Healthy cooperation is guaranteed

The team was able to show that maintaining the distance between the ERK particles leads to the prevention of this phosphorylation of the enzymes ERK 1 and ERK 2. This is the key to protecting against diseased cell growth. The teams identified a small protein sequence that keeps these ERK particles at a distance, thus guaranteeing the healthy cooperation of the protein molecules. The researchers named this protein sequence EDI, an acronym for ERK dimerisation inhibitor.

In the future, the principle of EDI could not only help patients suffering from cardiac insufficiency, but could also be applied in oncology. A class of therapeutics for the treatment of tumour diseases also targets the ERK enzymes, but switches off all ERK functions.

Help for cancer patients

Since ERK always has a protective function in the regulation of cellular processes, a complete switch-off of ERK can lead to severe side effects, particularly in the heart. The studies in animal models suggest that the use of EDI preserves the protective ERK effects and only switches off the pathological ERK components. In addition, the team has already been able to show in cell culture that EDI also slows down the growth of cancer cells.

"Now we want to pursue this therapeutic strategy in order to help patients suffering from cardiac insufficiency and the side effects of chemotherapy," said junior researchers Constanze Schanbacher and Theresa Brand giving an outlook on further research.

The work was financially supported by the German Federal Ministry of Education and Research, the Ministry of Innovation, Science and Research of North Rhine-Westphalia and the German Research Foundation.


Further press releases

24th January 2024

EfficientBioAI: New Open-Source Software Makes AI Models Lighter and Greener

Artificial intelligence has become an integral part of research. However, the better and more complex the models become, the higher their energy consumption. Researchers at ISAS and Peking University have therefore developed ready-to-use and open software that compresses existing bioimaging AI models. With the help of the new toolbox, scientists can now run their models faster and with significantly lower energy consumption.

Die Abbildung zeigt die 3D-Semantiksegmentierung von Osteozyten in Mäuseknochen vor und nach der Kompression des Modells mir EfficientBioAI Die Bilder wurden mittels Lichtblatt-Fluoreszenzmikroskopie aufgenommen.
11th December 2023

ComplexEye & AI Enable Faster Migration Analysis of Immune Cells

How and where immune cells such as neutrophil granulocytes migrate, for instance whether they infiltrate tumours, is crucial for cancer patients. They could benefit from drugs that prevent this migration. Until now, the migration behaviour of immune cells could only be investigated using conventional video microscopy. However, researchers at the University of Duisburg-Essen and ISAS have now developed the ComplexEye. With their new microscope for the high-throughput analysis of drug substances, they are now able to analyse significantly higher numbers of neutrophils for their migration behaviour.

Vergleich ComplexEye-Objektiv und 28,5-mm-Objektiv eines konventionellen Mikroskops.
11th November 2022

Chan Zuckerberg Initiative Funds Two Projects from Dortmund

To extend the image analysis platform napari, Chan Zuckerberg Initiative is funding two projects of the ISAS research groups AMBIOM - Analysis of Microscopic BIOMedical Images and Spatial Metabolomics.

Die linke Abbildung zeigt eine Mikroskop-Aufnahme von Tumor-Zellen. Auf der rechten Seite ist die Segmentierung mittels gängiger Computerprogramme zu sehen. Sobald die Zellen dicht nebeneinander liegen oder überlappen (s. blaue Markierung) verschlechtert sich die Segmentierung. Das vollautomatische Tracking führt daher im Ergebnis zu Ungenauigkeiten.
18th November 2021

Kristina Lorenz Wins Phoenix Prize

Prof. Dr. Kristina Lorenz and her team found a peptide agent against heart failure. For this achievment, Lorenz has been awarded the Phoenix Pharmacy Prize in the category "Pharmacology and Clinical Pharmacy".

Die Würzburger Professorin Kristina Lorenz mit den drei anderen Trägern des 2021er Phoenix Pharmazie-Wissenschaftspreises.
20th September 2021

New AMBIOM Group: Jianxu Chen Wants to Develop „Eyes & Brains“

Led by Dr Jianxu Chen, the junior research group AMBIOM plans to develop algorithms and methods that will allow countless image data worldwide to be analysed automatically, quickly and economically.

Dr. Jianxu Chen hat seine Forschungsarbeit am ISAS aufgenommen.
21st July 2021

New Method for Molecular Functionalization of Surfaces

An interdisciplinary team of scientists present a new approach on how stable and yet very well-ordered molecular single layers can be produced on silicon surfaces - by self-assembly.

Hochaufgelöstes Rastertunnelmikroskopie-Bild der geordneten NHC-Einzellage auf Silizium; NHC steht für "N-heterozyklische Carbene" (Ausschnitt).